淋巴瘤微小残留病检测：方法、程序和临床意义。
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance.
发表日期：2024
作者：
Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H Young, Xudong Zhang
来源：
Frontiers in Immunology
摘要：
淋巴瘤是一种高度异质性的淋巴造血肿瘤。随着我们对淋巴瘤生物学和病理学特征的了解不断加深，我们正在识别越来越多的淋巴瘤亚型。基因分型增强了我们诊断、治疗和监测淋巴瘤预后的能力。尽管治疗效果显着改善，但评估疾病反应和监测预后的传统方法并不完善，淋巴瘤患者的总体缓解率没有显着改善。微小残留病 (MRD) 通常表明存在难治性疾病或早期复发。对于淋巴瘤患者来说，个性化 MRD 监测技术提供了一种有效的方法来估计疾病缓解水平、预测早期复发风险和评估新药治疗方案的有效性。在这篇综述中，我们深入探讨了淋巴瘤的MRD程序，包括样本选择和要求、检测方法及其局限性和优点、结果解释。此外，我们还介绍了MRD检测在淋巴瘤中的临床应用。版权所有©2024 张，王，杨，丁，张，杨和张。
Lymphoma is a highly heterogeneous lymphohematopoietic tumor. As our understanding of the biological and pathological characteristics of lymphoma improves, we are identifying an increasing number of lymphoma subtypes. Genotyping has enhanced our ability to diagnose, treat, and monitor the prognosis of lymphoma. Despite significant improvements in treatment effectiveness, traditional methods for assessing disease response and monitoring prognosis are imperfect, and there is no significant improvement in overall remission rates for lymphoma patients. Minimal Residual Disease (MRD) is often indicative of refractory disease or early relapse. For lymphoma patients, personalized MRD monitoring techniques offer an efficient means to estimate disease remission levels, predict early relapse risk, and assess the effectiveness of new drug regimens. In this review, we delve into the MRD procedures in lymphoma, including sample selection and requirements, detection methods and their limitations and advantages, result interpretation. Besides, we also introduce the clinical applications of MRD detection in lymphoma.Copyright © 2024 Zhang, Wang, Yang, Ding, Zhang, Young and Zhang.